# A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

> **NCT06745518** · PHASE2 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 62 (actual)

## Conditions studied

- Hyperphosphatemia Patients on Hemodialysis

## Interventions

- **DRUG:** TS-172
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06745518
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-06
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-22
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745518, "A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06745518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*